In preparing this report ASPE staff conducted analyses of data, reviews of the literature, expert consultation, and stakeholder consultations.
We analyzed Medicare Part B data on prices and volumes of services for injectable oncology drugs. We also analyzed data from the Drug Shortage Program (DSP) at the Food and Drug Administration (FDA) and the University of Utah Drug Information System (DIS) sponsored by the AHSP. FDA conducted analyses of IMS data on behalf of the ASPE team.
We consulted with trade and pharmaceutical economists throughout the Federal government.
We spoke to stakeholders from four generic manufacturing companies, one wholesaler, the group purchasing association, and one group purchasing organization. We also spoke to representatives of hospitals and physicians associations.